{"id":63637,"date":"2026-07-01T00:00:00","date_gmt":"2026-06-30T17:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=63637"},"modified":"2026-07-01T00:00:00","modified_gmt":"2026-06-30T17:00:00","slug":"basecamp-research-brings-edens-antibiotic-and-vaccine-design-models-to-claude-science","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=63637","title":{"rendered":"Basecamp Research brings EDEN&#8217;s antibiotic and vaccine design models to Claude Science"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/3002092\/Basecamp_Research_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><i>Scientists can now design potent antibiotics and rapidly prioritise vaccine targets through Claude Science, thanks to integration with Basecamp Research&#8217;s EDEN models.<\/i><\/p>\n<p><span class=\"legendSpanClass\">LONDON and CAMBRIDGE, Mass.<\/span>, <span class=\"legendSpanClass\">July 1, 2026<\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/basecamp-research.com\/\" target=\"_blank\" rel=\"nofollow\">Basecamp Research<\/a>\u00a0today announced that its antibiotic design and vaccine target prediction EDEN models are now available through <i>Claude<\/i>, including Claude Science, Anthropic&#8217;s AI workbench for life sciences research. This allows researchers to generate and prioritise therapeutic candidates through a conversational interface in a matter of minutes. <\/p>\n<p>By combining Claude&#8217;s reasoning with EDEN&#8217;s biological design capabilities, researchers can now go straight from a target to a shortlist of high-performing antibiotic or vaccine candidates.\u00a0This capability is available in Claude.ai, Claude Desktop, Claude Mobile, Claude Code, Cowork, and Claude Science through Anthropic&#8217;s connectors directory.<\/p>\n<p><b>The world needs new antibiotics<\/b><\/p>\n<p>Drug-resistant infections play a role in nearly 5 million deaths per year, but the pharmaceutical industry has largely retreated from antibiotic development. New antibiotics are badly needed, particularly for the pathogens spreading fastest in lower-income countries where last-resort drugs are hardest to access.<\/p>\n<p>&#8220;Microbes have been producing antibiotics and evolving resistance to each other for billions of years,&#8221; said Glen Gowers, Co-founder and CEO of Basecamp Research. &#8220;EDEN learned from that history, and now, through Claude, researchers all over the world can design successful new antibiotics in minutes, not years.&#8221;<\/p>\n<p>In collaboration with University of Pennsylvania researchers, Basecamp Research demonstrated that 97% of the antibiotic peptides designed by EDEN are active against World Health Organisation (WHO)\u00a0 priority pathogens when tested in the lab. Fleming Prize winner and Presidential Associate Professor <a href=\"https:\/\/delafuentelab.seas.upenn.edu\/principal-investigator\/\" target=\"_blank\" rel=\"nofollow\">C\u00e9sar de la Fuente<\/a>\u00a0led the work by UPenn&#8217;s Machine Biology Group.<\/p>\n<p>One candidate, EDEN-7, was tested in mice infected with multidrug-resistant <i>Acinetobacter baumannii<\/i> \u2013 a pathogen associated with hospital outbreaks worldwide \u2013 and showed efficacy in the same range as a last-line antibiotic, despite being generated zero-shot, meaning the model produced it without subsequent optimization or iterative engineering.<\/p>\n<p>&#8220;This collaboration shows how frontier biological foundation models can be paired with rigorous experimental validation to accelerate antibiotic discovery,&#8221; de la Fuente said. &#8220;Antimicrobial resistance is one of the greatest existential threats facing humanity and collaborations like this between academia and industry are critical.&#8221;<\/p>\n<p><b>Finding vaccine targets in minutes<\/b><\/p>\n<p>Developing a vaccine against an emerging pathogen is a race against time. Which part of the pathogen to target is often determined empirically, which can take months of laboratory work.\u00a0 This delay often costs lives.<\/p>\n<p>EDEN&#8217;s vaccine design model identifies which proteins are most likely to trigger a protective immune response, outperforming comparable genomic foundation models. By integrating it into Claude, researchers can describe a problem in plain language and have Claude run a prioritisation workflow against the pathogen&#8217;s genetic sequence. This can reduce several weeks of research per pathogen into a single conversation.<\/p>\n<p><b>A growing collaboration<\/b><\/p>\n<p>&#8220;The antibiotic crisis and the need for new vaccines are two of the most important public health challenges of our time,&#8221; said Jonah Cool, Head of Life Sciences Partnerships and Deployment at Anthropic. &#8220;Making EDEN available through Claude Science gives researchers a new way to explore and prioritise treatments for some of the most dangerous pathogens on Earth.&#8221;<\/p>\n<p><b>Built on the world&#8217;s largest biological dataset<\/b><\/p>\n<p>Most biological AI models are trained on a narrow set of well-studied organisms \u2013 the ones scientists have already catalogued. In contrast, EDEN is trained on BaseData, the largest, fastest-growing and most information-rich biological database on Earth.<\/p>\n<p>To build it, Basecamp Research has run expeditions to over 200 locations across more than 30 countries, sampling the places life is strangest and least understood, including thermal springs, deep-sea sediment, polar ice, remote high-altitude plateaus. In the process, it has documented more than a million species new to science. The result is over 10 billion new genes and roughly ten times the content of every public database combined.<\/p>\n<p>Basecamp Research aims to scale BaseData 100-fold over the next two years through the Trillion Gene Atlas, a partnership with Anthropic, NVIDIA, PacBio and Ultima Genomics designed to generate genomic data at the trillion-gene scale for AI-driven drug discovery.<\/p>\n<p>Diversity is what drives EDEN&#8217;s performance across a wide range of tasks. Every sample is collected under informed-consent and benefit-sharing agreements so that the countries and communities who steward this biodiversity share in the value it creates, with each sequence traceable to one of hundreds of country-specific permits. This allows a portion of revenue to be fed back to the country and community where the data was originally sourced, setting a standard of data provenance that the rest of the field has yet to match.<\/p>\n<p><b>About Basecamp Research<\/b>\u00a0<br \/>Basecamp Research is dedicated to solving major challenges in healthcare and life sciences by exploring Beyond Known Biology\u2122. The company trains frontier AI models on BaseData, the world&#8217;s largest biological dataset, collected through partnerships with more than 200 organisations across more than 30 countries. Basecamp Research is developing a pipeline of therapeutics and works with commercial and academic partners worldwide to accelerate therapeutic discovery and development.<\/p>\n<p><i>BaseData\u2122, Beyond Known Biology\u2122, EDEN-GLM\u2122 and aiPGI\u2122 are trademarks and technologies of Basecamp Research.<\/i><\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/3002092\/Basecamp_Research_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><i>Scientists can now design potent antibiotics and rapidly prioritise vaccine targets through Claude Science, thanks to integration with Basecamp Research&#8217;s EDEN models.<\/i><\/p>\n<p><span class=\"legendSpanClass\">LONDON and CAMBRIDGE, Mass.<\/span>, <span class=\"legendSpanClass\">July 1, 2026<\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/basecamp-research.com\/\" target=\"_blank\" rel=\"nofollow\">Basecamp Research<\/a>\u00a0today announced that its antibiotic design and vaccine target prediction EDEN models are now available through <i>Claude<\/i>, including Claude Science, Anthropic&#8217;s AI workbench for life sciences research. This allows researchers to generate and prioritise therapeutic candidates through a conversational interface in a matter of minutes. <\/p>\n<p>By combining Claude&#8217;s reasoning with EDEN&#8217;s biological design capabilities, researchers can now go straight from a target to a shortlist of high-performing antibiotic or vaccine candidates.\u00a0This capability is available in Claude.ai, Claude Desktop, Claude Mobile, Claude Code, Cowork, and Claude Science through Anthropic&#8217;s connectors directory.<\/p>\n<p><b>The world needs new antibiotics<\/b><\/p>\n<p>Drug-resistant infections play a role in nearly 5 million deaths per year, but the pharmaceutical industry has largely retreated from antibiotic development. New antibiotics are badly needed, particularly for the pathogens spreading fastest in lower-income countries where last-resort drugs are hardest to access.<\/p>\n<p>&#8220;Microbes have been producing antibiotics and evolving resistance to each other for billions of years,&#8221; said Glen Gowers, Co-founder and CEO of Basecamp Research. &#8220;EDEN learned from that history, and now, through Claude, researchers all over the world can design successful new antibiotics in minutes, not years.&#8221;<\/p>\n<p>In collaboration with University of Pennsylvania researchers, Basecamp Research demonstrated that 97% of the antibiotic peptides designed by EDEN are active against World Health Organisation (WHO)\u00a0 priority pathogens when tested in the lab. Fleming Prize winner and Presidential Associate Professor <a href=\"https:\/\/delafuentelab.seas.upenn.edu\/principal-investigator\/\" target=\"_blank\" rel=\"nofollow\">C\u00e9sar de la Fuente<\/a>\u00a0led the work by UPenn&#8217;s Machine Biology Group.<\/p>\n<p>One candidate, EDEN-7, was tested in mice infected with multidrug-resistant <i>Acinetobacter baumannii<\/i> \u2013 a pathogen associated with hospital outbreaks worldwide \u2013 and showed efficacy in the same range as a last-line antibiotic, despite being generated zero-shot, meaning the model produced it without subsequent optimization or iterative engineering.<\/p>\n<p>&#8220;This collaboration shows how frontier biological foundation models can be paired with rigorous experimental validation to accelerate antibiotic discovery,&#8221; de la Fuente said. &#8220;Antimicrobial resistance is one of the greatest existential threats facing humanity and collaborations like this between academia and industry are critical.&#8221;<\/p>\n<p><b>Finding vaccine targets in minutes<\/b><\/p>\n<p>Developing a vaccine against an emerging pathogen is a race against time. Which part of the pathogen to target is often determined empirically, which can take months of laboratory work.\u00a0 This delay often costs lives.<\/p>\n<p>EDEN&#8217;s vaccine design model identifies which proteins are most likely to trigger a protective immune response, outperforming comparable genomic foundation models. By integrating it into Claude, researchers can describe a problem in plain language and have Claude run a prioritisation workflow against the pathogen&#8217;s genetic sequence. This can reduce several weeks of research per pathogen into a single conversation.<\/p>\n<p><b>A growing collaboration<\/b><\/p>\n<p>&#8220;The antibiotic crisis and the need for new vaccines are two of the most important public health challenges of our time,&#8221; said Jonah Cool, Head of Life Sciences Partnerships and Deployment at Anthropic. &#8220;Making EDEN available through Claude Science gives researchers a new way to explore and prioritise treatments for some of the most dangerous pathogens on Earth.&#8221;<\/p>\n<p><b>Built on the world&#8217;s largest biological dataset<\/b><\/p>\n<p>Most biological AI models are trained on a narrow set of well-studied organisms \u2013 the ones scientists have already catalogued. In contrast, EDEN is trained on BaseData, the largest, fastest-growing and most information-rich biological database on Earth.<\/p>\n<p>To build it, Basecamp Research has run expeditions to over 200 locations across more than 30 countries, sampling the places life is strangest and least understood, including thermal springs, deep-sea sediment, polar ice, remote high-altitude plateaus. In the process, it has documented more than a million species new to science. The result is over 10 billion new genes and roughly ten times the content of every public database combined.<\/p>\n<p>Basecamp Research aims to scale BaseData 100-fold over the next two years through the Trillion Gene Atlas, a partnership with Anthropic, NVIDIA, PacBio and Ultima Genomics designed to generate genomic data at the trillion-gene scale for AI-driven drug discovery.<\/p>\n<p>Diversity is what drives EDEN&#8217;s performance across a wide range of tasks. Every sample is collected under informed-consent and benefit-sharing agreements so that the countries and communities who steward this biodiversity share in the value it creates, with each sequence traceable to one of hundreds of country-specific permits. This allows a portion of revenue to be fed back to the country and community where the data was originally sourced, setting a standard of data provenance that the rest of the field has yet to match.<\/p>\n<p><b>About Basecamp Research<\/b>\u00a0<br \/>Basecamp Research is dedicated to solving major challenges in healthcare and life sciences by exploring Beyond Known Biology\u2122. The company trains frontier AI models on BaseData, the world&#8217;s largest biological dataset, collected through partnerships with more than 200 organisations across more than 30 countries. Basecamp Research is developing a pipeline of therapeutics and works with commercial and academic partners worldwide to accelerate therapeutic discovery and development.<\/p>\n<p><i>BaseData\u2122, Beyond Known Biology\u2122, EDEN-GLM\u2122 and aiPGI\u2122 are trademarks and technologies of Basecamp Research.<\/i><\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-63637","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/63637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63637"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/63637\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}